glp-1 pathway receptor agonists and DPP-4 inhibitors Pathway, Pharmacodynamics Frontiers | Exploring the multifaceted
Description
doi: 10.3389/fendo.2023.1210455
Once completed, companies compile data for regulatory submission to agencies such as the U.S
Without insurance, the drugs can cost $1,000 or more a month
Patients frequently experience improved cardiovascular health, better blood sugar control, reduced joint pain, and enhanced energy and mobility
